Rallybio (RLYB) announced the publication of a manuscript titled, “Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and ...

AK0610 is engineered from an antibody isolated from a recovered infant and targets the pre-fusion F protein of RSV.

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

(“ArkBio”) announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a ...

Scientists have created a novel technology for developing antibody (M6P) conjugates without enzyme modification in vitro, ...

The introduction of our first bispecific candidate for inflammatory diseases, CDX-622, builds on our leadership in mast cell biology,” said Anthony Marucci, Co-founder, President and Chief Executive ...

A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients ...

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the decision to submit a Biologics License Application (BLA) in the U.S. for ...

Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for the treatment of prostate cancer and other cancers, today ...

The rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...

Research and development expenses were $2.6 million for the three months ended September 30, 2024, compared to $1.1 million for the same period in 2023. The increase was primarily attributable to ...

All other infusion-related and hypersensitivity reactions were mild or moderate. Covid-19 monoclonal antibodies are needed to protect immunocompromised persons who may not mount an adequate ...